kentucky semaglutide vomiting class action in The expanding role of semaglutide: beyond glycemic control FDA warns consumers not to

For most affected participants, the symptoms were manageable and did not lead to treatment discontinuation, but it represents a novel consideration that researchers should be aware of

But some people may feel uncomfortable talking to their doctors because of stigma about weight

False marketing : Social-media ads often make exaggerated claims (lose 30 kg in 8 weeks etc.) without reflecting the true context of medical supervision, lifestyle change, eligibility criteria or monitoring

[DOI] [PMC free article] [PubMed] [Google Scholar] [41].Pang J, Cen C, Tian Y, Cao X, Hao L, Tao X, et al

Together, that helps explain why bloating, gas, and constipation are common, especially early on and during dose increases

GLP-1 surprises